美国 NeuroSigma  
位于加利福尼亚州洛杉矶市的NeuroSigma公司的新产品——Monarch外部三叉神经激发(eTNS)系统已经通过欧盟批准。在产品发布会上，该公司把它被定义为9岁及以上癫痫和抑郁症患者的辅助治疗系统。

NeuroSigma, Inc. is a medical device company based in Westwood, California. NeuroSigma has a growing pipeline of treatments targeting epilepsy, depression, post-traumatic stress disorder (PTSD), obesity, among others and is actively engaged in cutting-edge preclinical research and development, as well as groundbreaking Phase I and Phase II clinical trials. NeuroSigma is utilizing two distinct therapy platforms:

Deep Brain Stimulation (DBS) - Pioneered in France for the treatment of essential tremor and Parkinson’s disease. New therapies in development by NeuroSigma.

Trigeminal Nerve Stimulation (TNS) - A proprietary therapy developed at the University of California, Los Angeles and exclusively licensed to NeuroSigma.

CAUTION: The TNS and DBS therapies being developed by NeuroSigma are investigational therapies and limited by United States law for investigational use.